EMEA-001577-PIP03-17 - paediatric investigation plan
emtricitabine
tenofovir alafenamide
PIPHuman
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com
Tel. +44 (0)1223 897300
P/0139/2018: EMA decision of 7 May 2018 on the agreement of a paediatric investigation plan and on the granting of a waiver for emtricitabine / tenofovir alafenamide (Descovy), (EMEA-001577-PIP03-17)